- BriaCell Therapeutics Corp. is working to develop the first off-the-shelf personalized immunotherapy for advanced breast cancer
- Clinical data reveals an excellent safety profile and potent anti-tumor activity for Bria-IMT in advanced breast cancer patients
- Combination study using Bria-IMT with Merck & Co., Inc.’s KEYTRUDA (pembrolizumab) in advanced breast cancer patients is ongoing
- Symposium covers the latest research on experimental biology, etiology, prevention, diagnosis and treatment of breast cancer and premalignant breast disease
- International audience from over 90 countries includes researchers, health professionals, physicians, oncologists and those with a special interest in breast cancer
An immuno-oncology focused biotechnology company, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) will present details of its proprietary targeted immunotherapy technology in patients with advanced breast cancer during a poster session of the 2018 San Antonio Breast Cancer Symposium, scheduled for December 4-8 in San Antonio, Texas. Highlights of the company’s data on Bria-IMT as a monotherapy, demonstrating positive proof-of-concept and an initial assessment of safety and tolerability for Bria-IMT in combination with pembrolizumab (KEYTRUDA, manufactured by Merck & Co., Inc.) in advanced breast cancer patients, will be presented.
Presenting the poster will be Saveri Bhattacharya, DO, (http://ibn.fm/K2lpm) assistant professor of medical oncology at Thomas Jefferson University (http://ibn.fm/6UqCV), researcher at the NCI-designated Sidney Kimmel Cancer Center (http://ibn.fm/uapyF) at Jefferson Health (http://ibn.fm/MJJVW) and principal investigator (PI) of the study. BriaCell’s scientific team will be available to answer questions during the poster presentation.
Identified as poster no. 212 during the treatment immunotherapy (clinical) session and with the title “Initial safety and efficacy of a phase I/IIa trial of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer,” BriaCell’s poster presentation is slated for Thursday, December 6, from 7:30 am to 9:00 am CT at the Henry B. Gonzalez Convention Center at 900 E. Market Street in San Antonio, Texas. The combination study is also listed on ClinicalTrials.gov with the National Institutes of Health as NCT03328026.
Improving the efficacy, safety and cost of care for those who are annually diagnosed with breast cancer continues to be at the forefront of medical research. An estimated 266,120 new cases of breast cancer are projected to be diagnosed in U.S. women during 2018, according to the National Cancer Institute (NCI) (http://ibn.fm/cUSKe). Female breast cancer represents 15.3 percent of all new cancer cases in the U.S., with nearly 41,000 women expected to die of the disease in 2018, according to the NCI. Breast cancer is identified as the most commonly occurring cancer in women around the globe and the second most common cancer overall, according to the World Cancer Research Fund International (http://ibn.fm/sVNYK).
”Early clinical findings of BriaCell’s novel, personalized immunotherapy treatment approach is generating great excitement,” Dr. Bill Williams, BriaCell’s president and CEO, noted in a news release.
“Bria-IMT has demonstrated positive proof-of-concept in advanced breast cancer, and we will delve into these data in San Antonio’s Breast Cancer conference which is a key oncology conference attended by leading scientists and oncologists worldwide. We have firm grounds to believe the anti-tumor effects of Bria-IMT can be greatly improved by combination with KEYTRUDA,” Williams continued (http://ibn.fm/O9cgn). “As we advance our technology and generate additional data, we will continue to discuss our novel therapeutic approach with potential partners to explore additional combinations. With the potential for a safe and effective treatment option for advanced breast cancer patients, we are committed to developing the shortest possible pathway to make these therapies available to these patients.”
Following the presentation at the symposium, copies of the abstract and poster will be available on www.BriaCell.com/Investor-Relations/Presentations
For more information, visit the company’s website at www.BriaCell.com
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.